PortfoliosLab logoPortfoliosLab logo
CVKD vs. AYTU
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CVKD vs. AYTU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Cadrenal Therapeutics Inc. Common Stock (CVKD) and Aytu BioPharma, Inc. (AYTU). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CVKD achieves a -35.84% return, which is significantly lower than AYTU's -19.23% return.


CVKD

1D
-7.45%
1M
-31.50%
YTD
-35.84%
6M
-47.40%
1Y
-67.87%
3Y*
-40.40%
5Y*
10Y*

AYTU

1D
-2.33%
1M
-19.54%
YTD
-19.23%
6M
2.44%
1Y
17.98%
3Y*
4.89%
5Y*
-54.20%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

CVKD vs. AYTU - Yearly Performance Comparison


2026 (YTD)202520242023
CVKD
Cadrenal Therapeutics Inc. Common Stock
-35.84%-53.21%30.56%-82.04%
AYTU
Aytu BioPharma, Inc.
-19.23%52.94%-40.14%-19.77%

Correlation

The correlation between CVKD and AYTU is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.20

Correlation (3Y)
Calculated over the trailing 3-year period

0.13

Correlation (All Time)
Calculated using the full available price history since Jan 23, 2023

0.12

Fundamentals

Market Cap

CVKD:

$8.67M

AYTU:

$22.07M

EPS

CVKD:

-$5.10

AYTU:

-$2.91

PB Ratio

CVKD:

3.17

AYTU:

0.63

Total Revenue (TTM)

CVKD:

$0.00

AYTU:

$56.60M

Gross Profit (TTM)

CVKD:

-$5.92K

AYTU:

$36.14M

EBITDA (TTM)

CVKD:

-$13.32M

AYTU:

-$27.34M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CVKD vs. AYTU — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CVKD
CVKD Risk / Return Rank: 99
Overall Rank
CVKD Sharpe Ratio Rank: 1212
Sharpe Ratio Rank
CVKD Sortino Ratio Rank: 1111
Sortino Ratio Rank
CVKD Omega Ratio Rank: 1313
Omega Ratio Rank
CVKD Calmar Ratio Rank: 44
Calmar Ratio Rank
CVKD Martin Ratio Rank: 44
Martin Ratio Rank

AYTU
AYTU Risk / Return Rank: 5252
Overall Rank
AYTU Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
AYTU Sortino Ratio Rank: 5151
Sortino Ratio Rank
AYTU Omega Ratio Rank: 5151
Omega Ratio Rank
AYTU Calmar Ratio Rank: 5252
Calmar Ratio Rank
AYTU Martin Ratio Rank: 5353
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CVKD vs. AYTU - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Cadrenal Therapeutics Inc. Common Stock (CVKD) and Aytu BioPharma, Inc. (AYTU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CVKDAYTUDifference

Sharpe ratio

Return per unit of total volatility

-0.69

0.27

-0.96

Sortino ratio

Return per unit of downside risk

-0.97

0.92

-1.89

Omega ratio

Gain probability vs. loss probability

0.89

1.12

-0.23

Calmar ratio

Return relative to maximum drawdown

-0.93

0.51

-1.44

Martin ratio

Return relative to average drawdown

-1.56

1.23

-2.78

CVKD vs. AYTU - Sharpe Ratio Comparison

The current CVKD Sharpe Ratio is -0.69, which is lower than the AYTU Sharpe Ratio of 0.27. The chart below compares the historical Sharpe Ratios of CVKD and AYTU, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


CVKDAYTUDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.69

0.27

-0.96

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.64

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.54

-0.36

-0.18

Drawdowns

CVKD vs. AYTU - Drawdown Comparison

The maximum CVKD drawdown since its inception was -93.12%, smaller than the maximum AYTU drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for CVKD and AYTU.


Loading charts...

Drawdown Indicators


CVKDAYTUDifference

Max Drawdown

Largest peak-to-trough decline

-93.12%

-100.00%

+6.88%

Max Drawdown (1Y)

Largest decline over 1 year

-72.56%

-35.47%

-37.09%

Max Drawdown (3Y)

Largest decline over 3 years

-87.41%

-70.24%

-17.17%

Max Drawdown (5Y)

Largest decline over 5 years

-99.12%

Current Drawdown

Current decline from peak

-92.96%

-100.00%

+7.04%

Average Drawdown

Average peak-to-trough decline

-78.76%

-95.14%

+16.38%

Ulcer Index

Depth and duration of drawdowns from previous peaks

43.22%

14.66%

+28.56%

Volatility

CVKD vs. AYTU - Volatility Comparison

Cadrenal Therapeutics Inc. Common Stock (CVKD) has a higher volatility of 17.91% compared to Aytu BioPharma, Inc. (AYTU) at 12.52%. This indicates that CVKD's price experiences larger fluctuations and is considered to be riskier than AYTU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CVKDAYTUDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.91%

12.52%

+5.39%

Volatility (6M)

Calculated over the trailing 6-month period

81.65%

33.97%

+47.68%

Volatility (1Y)

Calculated over the trailing 1-year period

98.78%

66.08%

+32.70%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

101.10%

85.63%

+15.47%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

101.10%

188.35%

-87.25%

Dividends

CVKD vs. AYTU - Dividend Comparison

Neither CVKD nor AYTU has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

CVKD vs. AYTU - Financials Comparison

This section allows you to compare key financial metrics between Cadrenal Therapeutics Inc. Common Stock and Aytu BioPharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M25.00M30.00M35.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober20260
12.41M
(CVKD) Total Revenue
(AYTU) Total Revenue
Values in USD except per share items

Frequently Asked Questions


CVKD and AYTU have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CVKD has higher volatility (17.91%) compared to AYTU (12.52%). In terms of maximum drawdown, CVKD dropped -93.12% vs AYTU's -100.00%.

AYTU currently has the higher Sharpe Ratio (0.27 vs -0.69), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CVKD and AYTU

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer